Information on Invega Sustenna Dosage: Its Form, Strengths, Administration, and Further Details
Invega Sustenna is a prescription drug used to treat schizophrenia or schizoaffective disorder in adults. This atypical antipsychotic, whose active ingredient is paliperidone palmitate, comes in the form of an injectable suspension in a prefilled syringe.
The recommended starting dosage for schizoaffective disorder treatment is 234 mg on Day 1 and 156 mg on Day 8. After this initial loading phase, the maintenance dosage ranges from 39 to 234 mg per month, with the typical maintenance dose being 117 mg once per month. For schizophrenia treatment, the starting dosage and maintenance dosage follow a similar pattern.
Invega Sustenna is administered by a healthcare professional in a clinical setting. The injection is given intramuscularly, with loading doses typically given into the upper arm and monthly doses into the upper arm or buttocks muscle. About 5 weeks after the first injection, you'll begin once-monthly maintenance injections for schizoaffective disorder.
It's important to note that your doctor may adjust your dosage over the course of your treatment. The length of treatment should be discussed with your doctor, as Invega Sustenna is a long-term treatment for schizoaffective disorder.
While there were no reports of Invega Sustenna overdoses in clinical trials, overdoses of oral paliperidone (Invega) have been reported. Symptoms of paliperidone overdose can include unsteady walk, extrapyramidal symptoms, drowsiness, and QT prolongation. If you think you've received too much Invega Sustenna, call your doctor right away or contact America's Poison Centers or its online resource. If you have severe symptoms, immediately call 911 or go to the nearest emergency room.
As with any medication, it's crucial to use Invega Sustenna as directed by your doctor. The drug comes in the following strengths: 39 mg, 78 mg, 117 mg, 156 mg, and 234 mg.
While there is no publicly available specific information about which medical associations in Germany explicitly requested the prescription of Invega Sustenna for schizophrenia and schizoaffective disorder in adults in 2019 and 2020, it remains a valuable treatment option for those suffering from these conditions. Always consult with your healthcare provider for personalised medical advice.
Read also:
- Peptide YY (PYY): Exploring its Role in Appetite Suppression, Intestinal Health, and Cognitive Links
- Toddler Health: Rotavirus Signs, Origins, and Potential Complications
- Digestive issues and heart discomfort: Root causes and associated health conditions
- House Infernos: Deadly Hazards Surpassing the Flames
